Exposure to dideoxynucleosides is reflected in lowered mitochondrial DNA in subcutaneous fat

Journal of Acquired Immune Deficiency Syndromes

Volumn 30, Issue 3, 2002, Pages 271-277

  Cherry, Catherine L ^a   Gahan, Michelle E ^a   McArthur, Justin C ^a   Lewin, Sharon R ^a   Hoy, Jennifer F ^a   Wesselingh, Steven L ^a  

^a ALFRED HOSPITAL   (Australia)

Author keywords

Dideoxynucleosides; HIV; Lactate; Mitochondrial DNA

Indexed keywords

2',3' DIDEOXYNUCLEOSIDE DERIVATIVE; ANTIRETROVIRUS AGENT; DIDANOSINE; MITOCHONDRIAL DNA; NUCLEOSIDE ANALOG; STAVUDINE; ZALCITABINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG EXPOSURE; HUMAN; LACTATE BLOOD LEVEL; MAJOR CLINICAL STUDY; MONONUCLEAR CELL; MUSCLE BIOPSY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SUBCUTANEOUS FAT;

EID: 0036640489     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/00126334-200207010-00002     Document Type: Article

References (29)

1. HIV disease progression in Australia in the time of combination antiretroviral therapies
2. Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: Prospective multicentre study. Swiss HIV Cohort Study
3. Impact of protease inhibitors on AIDS-defining events and hospitalizations in 10 French AIDS reference centers
4. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection
5. Impact of combination therapy for HIV infection on inpatient census
6. You've gotta have HAART
7. Mitochondrial toxicity induced by nucleoside-analog reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy
8. HIV nucleoside analogues: New adverse effects on mitochondria?
9. Mitochondrial toxicity of antiviral drugs
10. Nucleoside reverse transcriptase inhibitor-induced mitochondrial toxicity as an etiology for lipodystrophy
11. Delayed cytotoxicity and selective loss of mitochondrial DNA in cells treated with the anti-human immunodeficiency virus compound 2′,3′-dideoxycytidine
12. Stavudine-induced macrocytosis during therapy for human immunodeficiency virus infection
13. Toxicity of antiretroviral agents
14. Pharmacology of nucleoside and nucleotide reverse transcriptase inhibitor-induced mitochondrial toxicity
15. Effect of anti-human immunodeficiency virus nucleoside analogs on mitochondrial DNA and its implication for delayed toxicity
16. Adverse effects of reverse transcriptase inhibitors: Mitochondrial toxicity as common pathway
17. Mitochondrial toxicity of antiviral nucleoside analogues
18. A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analog therapy: Contribution to protease inhibitor-related lipodystrophy syndrome
19. Hyperlactatemia and hepatic abnormalities in 10 human immunodeficiency virusinfected patients receiving nucleoside analogue combination regimens
20. Lactate concentrations distinguish between nucleoside neuropathy and HIV distal symmetrical sensory polyneuropathy
21. Acetyl-carnitine deficiency in AIDS patients on treatment with antiretroviral nucleoside analogues
22. L-acetyl carnitine therapy increases cutaneous innervation and improves symptoms in antiretroviral related HIV peripheral neuropathy
23. Quantification of mitochondrial DNA in peripheral blood mononuclear cells and subcutaneous fat using real-time polymerase chain reaction
24. Cutaneous innervation in sensory neuropathies: Evaluation by skin biopsy
25. Measuring recent thymic emigrants in blood of normal persons and HIV-1-infected patients before and after effective therapy
26. The mitochondrial theory of aging
27. Age-related structural and functional changes of brain mitochondria
28. Decreased susceptibility to oxidative stress-induced apoptosis of peripheral blood mononuclear cells from healthy elderly and centenarians
29. Chronic hyperlactatemia in HIV-infected patients taking antiretroviral therapy